AUS
NZ
UK
CA
USA
IND
Highlights
- CU6 has welcomed Prof Emmett, a leading cancer research expert, to its Scientific Advisory Board.
- Prof Emmett is committed to aiding the company in developing novel radiopharmaceuticals.
- She is heavily involved in Australia’s multidisciplinary clinical development and cancer research efforts.
Clarity Pharmaceuticals (ASX:CU6) has bolstered its Scientific Advisory Board (SAB) with the addition of a leading nuclear medicine and theranostics expert. The clinical-stage radiopharmaceutical company has appointed Professor Louise Emmett to the SAB.
Prof Emmett has been the company’s long-term collaborator. She has aided the company in swiftly advancing Phase I studies in breast and prostate cancers, backed by her in-depth knowledge of the radiopharmaceutical space and expertise in navigating the early-stage clinical trial scene in Australia.
CU6 share price up 11%
CU6 shares saw a significant jump in its share price post the update. The shares rallied by over 11% to AU$0.545 midday on 29 June 2022. The company has a market capitalisation of AU$126.38 million.
In the last one month, the stock has delivered a return of more than 9%.
About Professor Louise Emmett
Prof Emmett has a huge role in advancing SAR-Bombesin and SAR-bisPSMA products. Earlier this month, she presented data from the pilot diagnostic trial of SAR-Bombesin in breast cancer at the 2022 Annual Meeting of the reputed American Society of Clinical Oncology (ASCO).
Additionally, she has successfully imaged several prostate cancer patients who are PSMA-negative under a Special Access Scheme in Australia, laying a foundation for Clarity's lately approved US-based Phase II trial with SAR-Bombesin in this indication. Moreover, she is offering her services to several potential randomised studies as a principal investigator.
Prof Emmett current roles (source: company update)
Education
Prof Emmett secured a degree in 2014 from Auckland University as a Doctor of Medicine in Nuclear Cardiology.
Besides obtaining several clinical research grants, she has been a part of peer-reviewed journals, contributing more than 100 original papers in the last one decade.
She is looking forward to continuing her collaboration with Clarity, now as a member of the SAB, to develop novel radiopharmaceuticals to improve treatment outcomes for cancer-affected children and adults.
